Description
A metabolite of all-trans retinoic acid; formed through metabolism of all-trans retinoic acid by CYP26A1, B1, and C1; binds to RARs with a lower affinity than other all-trans retinoic acid metabolites (IC50s = 606, 298, and 892 nM for RARα, RARβ, and RARγ, respectively, in a radioligand binding assay); transactivates RARs with a lower efficacy than other metabolites (EC50s = 791, 64, and 94 nM for RARα, RARβ, and RARγ, respectively) but induces transcription of a reporter plasmid equipotently; inhibits cell growth, halts the cell cycle in the G1 phase, and induces differentiation of NB4 acute promyelocytic leukemia cells (EC50 = 79.8 nM)
Formal name: 4-hydroxy-retinoic acid
Synonyms: 4-hydroxy RA|4-OH-atRA
Molecular weight: 316.4
CAS: 66592-72-1
Purity: ≥95%
Formulation: A solid
Product Type|Biochemicals|Receptor Pharmacology|Agonists||Product Type|Biochemicals|Xenobiotic Metabolites||Research Area|Cancer|Cell Cycle|G1